Patents by Inventor Mats Hellstrom

Mats Hellstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100119526
    Abstract: DLL4-binding antibodies, specifically antibodies preventing Notch signaling and internalization of DLL4, can: more efficiently than inhibitors only preventing DLL4-mediated Notch-signaling disrupt angiogenesis and pathological processes including tumor growth.
    Type: Application
    Filed: January 28, 2008
    Publication date: May 13, 2010
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Mats Hellström
  • Publication number: 20090209473
    Abstract: Angiogenesis may be initiated or increased through the use of gamma-secretase inhibitors. The gamma-secretase inhibitor can be a dipeptide class, sulfonamide class, transition state mimic class, benzodiazepine class, or benzocaprolactam class gamma secretase inhibitor. Methods for initiating and increasing angiogenesis are used for disease prevention and treatment as well as for generating research models.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 20, 2009
    Inventors: Mats Hellstrom, Linda Karlsson-Lindahl, Elisabet Wallgard
  • Publication number: 20090036362
    Abstract: The present invention relates to polynucleotides and proteins associated with vasculogenesis- and angiogenesis-related disorders. The invention further relates to methods for the identification of compounds that modulate the expression of angiogenesis-related genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, and to methods and compositions for the treatment these disorders.
    Type: Application
    Filed: December 6, 2004
    Publication date: February 5, 2009
    Applicant: AngioGenetics Sweden AB
    Inventors: Mats Hellstrom, Elisabet Wallgard, Mattias Kalen
  • Publication number: 20070142308
    Abstract: Angiogenesis may be affected by administering a compound to a group of cells, a tissue or an organism. Such affect may be to inhibit or stimulate angiogenesis. The compounds may be used to treat disease states related to insufficient or unregulated angiogenesis.
    Type: Application
    Filed: October 2, 2006
    Publication date: June 21, 2007
    Inventors: Helmut Augustin, Mats Hellstrom
  • Publication number: 20070142433
    Abstract: Angiogenesis may be affected by administering a compound to a group of cells, a tissue or an organism. Such affect may be to inhibit or stimulate angiogenesis. The compounds may be used to treat disease states related to insufficient or unregulated angiogenesis.
    Type: Application
    Filed: October 17, 2006
    Publication date: June 21, 2007
    Inventors: Helmut Augustin, Mats Hellstrom
  • Publication number: 20060264380
    Abstract: Angiogenesis may be initiated or increased through the use of gamma-secretase inhibitors. The gamma-secretase inhibitor can be a dipeptide class, sulfonamide class, transition state mimic class, benzodiazepine class, or benzocaprolactam class gamma secretase inhibitor. Methods for initiating and increasing angiogenesis are used for disease prevention and treatment as well as for generating research models.
    Type: Application
    Filed: January 18, 2006
    Publication date: November 23, 2006
    Inventors: Mats Hellstrom, Linda Karlsson, Elisabeth Wallgard